Altimmune (ALT) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.
- Altimmune's Net Income towards Common Stockholders rose 1676.95% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 1882.44%. This contributed to the annual value of -$95.1 million for FY2024, which is 752.99% down from last year.
- Per Altimmune's latest filing, its Net Income towards Common Stockholders stood at -$19.0 million for Q3 2025, which was up 1676.95% from -$22.1 million recorded in Q2 2025.
- Altimmune's 5-year Net Income towards Common Stockholders high stood at -$14.9 million for Q1 2021, and its period low was -$33.5 million during Q3 2021.
- Its 5-year average for Net Income towards Common Stockholders is -$22.4 million, with a median of -$22.1 million in 2025.
- As far as peak fluctuations go, Altimmune's Net Income towards Common Stockholders crashed by 28253.86% in 2021, and later skyrocketed by 2983.29% in 2022.
- Quarter analysis of 5 years shows Altimmune's Net Income towards Common Stockholders stood at -$23.9 million in 2021, then rose by 9.33% to -$21.7 million in 2022, then plummeted by 46.08% to -$31.6 million in 2023, then grew by 26.37% to -$23.3 million in 2024, then increased by 18.39% to -$19.0 million in 2025.
- Its Net Income towards Common Stockholders was -$19.0 million in Q3 2025, compared to -$22.1 million in Q2 2025 and -$19.6 million in Q1 2025.